508 / 1816
Absolute incidence of ipsilat breast recurrences*
Remarks
F-up (yr)
BCS BCS + RT
EORTC 10853
1
15
31% 18%
NSABP-17
2
17
35% 20%
SweDCIS
3
20
32% 20%
UK/ANZ
4
+/ - Tamoxifen
12
17% 2.6%
*: in all trials, about 50% of recurrences concerns an invasive recurrence
1
Donker et al JCO 2013
2
Wapnir et al JNCI 2011
3
Warnberg et al JCO 2014
4
Cuzick et al Lancet Oncol 2012